000			nab a22 7a 4500
999			_c17337 _d17337
003			PC17337
005			20230327120752.0
008			230327b xxu||||| |||| 00| 0 eng d
040			_cH12O
041			_aeng
100			_9891 _aVanaclocha Sebastián, Francisco _eDermatología Médico Quirúrgica y Venereología
100			_9889 _aRivera Díaz, Raquel _eDermatología Médico-Quirúrgica y Venereología
245	0	0	_aRisk of adverse events in psoriasis patients receiving classic systemic drugs and biologics in a 5-year observational study of clinical practice: 2008-2013 results of the Biobadaderm registry. _h[artículo]
260			_bJournal of the European Academy of Dermatology and Venereology : JEADV, _c2015
300			_a29(1):156-63.
500			_aFormato Vancouver: Carretero G, Ferrandiz C, Dauden E, Vanaclocha Sebastián F, Gómez García FJ, Herrera Ceballos E et al; BIOBADADERM Study Group. Risk of adverse events in psoriasis patients receiving classic systemic drugs and biologics in a 5-year observational study of clinical practice: 2008-2013 results of the Biobadaderm registry. J Eur Acad Dermatol Venereol. 2015 Jan;29(1):156-63.
501			_aPMID: 24684267
504			_aContiene 18 referencias
520			_aBackground: Biobadaderm is the Spanish registry of psoriasis patients receiving systemic treatment in clinical practice. Objective: To compare the safety of biologics and classic systemic treatment. Methods: Prospective cohort of patients receiving biologics and classic systemic therapies between 2008 and 2013 in 12 hospitals are included. We registered demographic data, diagnoses, comorbidities, treatments and adverse events (AE). We obtained raw relative risks (RR) for specific AE. Multivariate analysis consisted of Cox models adjusting for age, gender, chronic hepatic disease and previous cancer. Results: A total of 1030 patients received biologics (2061 AE in 3681 person-years), 926 patients classic systemic drugs (1015 AE in 1517 person-years). Ninety-three per cent of AE in both groups were non-serious, 6% serious and 0.003% fatal. The age- and gender-adjusted hazard ratio of AE was lower in the biologics group [hazard ratio 0.6 (95% CI: 0.5-0.7)].We found no differences in rates of serious and mortal AE. Some system organ class AE rates differed between both groups. As limitations: Prescription bias might affect the incidence of AE in both groups. Association of drug and AE was based on timing: associations might not be causal. Conclusion: Patients receiving biologics had lower risk of AE. We did not find differences in the risk of serious or fatal AE.
710			_9145 _aServicio de Dermatología Médico-Quirúrgica y Venereología
856			_uhttp://pc-h12o-es.m-hdoct.a17.csinet.es/pdf/pc/1/pc17337.pdf _ySolicitar documento
942			_2ddc _cART _n0